Erik Rahimi1, Sachin Batra1, Nirav Thosani1, Harminder Singh2, Sushovan Guha3. 1. Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Medical School at Houston, 6431 Fannin, MSB 4.234, Houston, TX, 77030, USA. 2. Section of Gastroenterology, University of Manitoba and CancerCare Manitoba, 805-715 McDermot Avenue, Winnipeg, MB, R3E3P4, Canada. Harminder.Singh@umanitoba.ca. 3. Division of Gastroenterology, Hepatology, and Nutrition, University of Texas Medical School at Houston, 6431 Fannin, MSB 4.234, Houston, TX, 77030, USA. Sushovan.Guha@uth.tmc.edu.
Abstract
BACKGROUND: Identifying high-risk groups for pancreatic cancer (PC) may lead to earlier detection. We determined the risk of subsequent PC among survivors of sporadic colorectal cancer (CRC). METHODS: We evaluated data from the US Surveillance, Epidemiology, and End Results registry to identify individuals with primary CRC between the years 1973-2006. Standardized incidence ratios (SIRs) and 95 % confidence interval (95 % CI) were calculated to compare the risk of subsequent primary PC in the study cohort to that of the standard population. Analysis was stratified by age at diagnosis of CRC and sex. CRC characteristics were compared among CRC survivors with and without PC. Multivariate sub-hazard ratios were calculated to identify factors associated with subsequent primary PC, using death from non-PC causes as a competing event. RESULTS: Of the 273,144 patients with first primary CRC, 657 (0.24 %) developed subsequent PC. CRC survivors were more likely to develop PC (SIR 1.22; 95 % CI 1.09-1.35). Mean latency period (time between CRC and PC diagnosis) was 1, 3, and 5 years from index age of CRC 20-49, 50-64, and >65 years, respectively. Multivariate analysis showed CRC survivors >50 years had 3.5-fold, those with right-sided CRC had 1.2-fold, and those with localized and regional CRCs had sixfold and fivefold increased risk of PC, respectively. CONCLUSION: This study suggests that CRC survivors have an increased risk of developing subsequent PC within 1-5 years. CRC survivors age >50 with localized/regional stage, and right-sided CRC have higher predisposition to PC.
BACKGROUND: Identifying high-risk groups for pancreatic cancer (PC) may lead to earlier detection. We determined the risk of subsequent PC among survivors of sporadic colorectal cancer (CRC). METHODS: We evaluated data from the US Surveillance, Epidemiology, and End Results registry to identify individuals with primary CRC between the years 1973-2006. Standardized incidence ratios (SIRs) and 95 % confidence interval (95 % CI) were calculated to compare the risk of subsequent primary PC in the study cohort to that of the standard population. Analysis was stratified by age at diagnosis of CRC and sex. CRC characteristics were compared among CRC survivors with and without PC. Multivariate sub-hazard ratios were calculated to identify factors associated with subsequent primary PC, using death from non-PC causes as a competing event. RESULTS: Of the 273,144 patients with first primary CRC, 657 (0.24 %) developed subsequent PC. CRC survivors were more likely to develop PC (SIR 1.22; 95 % CI 1.09-1.35). Mean latency period (time between CRC and PC diagnosis) was 1, 3, and 5 years from index age of CRC 20-49, 50-64, and >65 years, respectively. Multivariate analysis showed CRC survivors >50 years had 3.5-fold, those with right-sided CRC had 1.2-fold, and those with localized and regional CRCs had sixfold and fivefold increased risk of PC, respectively. CONCLUSION: This study suggests that CRC survivors have an increased risk of developing subsequent PC within 1-5 years. CRC survivors age >50 with localized/regional stage, and right-sided CRC have higher predisposition to PC.
Entities:
Keywords:
Colon cancer; Pancreatic cancer; Risk factors; Second primary; Sporadic
Authors: Sunil Amin; Russell B McBride; Jennie K Kline; Elana B Mitchel; Aimee L Lucas; Alfred I Neugut; Harold Frucht Journal: Cancer Date: 2011-09-01 Impact factor: 6.860
Authors: J Young; L A Simms; K G Biden; C Wynter; V Whitehall; R Karamatic; J George; J Goldblatt; I Walpole; S A Robin; M M Borten; R Stitz; J Searle; D McKeone; L Fraser; D R Purdie; K Podger; R Price; R Buttenshaw; M D Walsh; M Barker; B A Leggett; J R Jass Journal: Am J Pathol Date: 2001-12 Impact factor: 4.307
Authors: Min Shen; Paolo Boffetta; Jørgen H Olsen; Aage Andersen; Kari Hemminki; Eero Pukkala; Elizabeth Tracey; David H Brewster; Mary L McBride; Vera Pompe-Kirn; Erich V Kliewer; Jon M Tonita; Kee-Seng Chia; Carmen Martos; Jon G Jonasson; Didier Colin; Ghislaine Scélo; Paul Brennan Journal: Am J Epidemiol Date: 2006-01-18 Impact factor: 4.897
Authors: Aung Ko Win; Rhiannon J Walters; Daniel D Buchanan; Mark A Jenkins; Kevin Sweet; Wendy L Frankel; Albert de la Chapelle; Diane M McKeone; Michael D Walsh; Mark Clendenning; Sally-Ann Pearson; Erika Pavluk; Belinda Nagler; John L Hopper; Michael R Gattas; Jack Goldblatt; Jill George; Graeme K Suthers; Kerry D Phillips; Sonja Woodall; Julie Arnold; Kathy Tucker; Michael Field; Sian Greening; Steve Gallinger; Melyssa Aronson; Renee Perrier; Michael O Woods; Jane S Green; Neal Walker; Christophe Rosty; Susan Parry; Joanne P Young Journal: Am J Gastroenterol Date: 2012-04-24 Impact factor: 10.864
Authors: Alina Vrieling; H Bas Bueno-de-Mesquita; Hendriek C Boshuizen; Dominique S Michaud; Marianne T Severinsen; Kim Overvad; Anja Olsen; Anne Tjønneland; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Sabine Rohrmann; Heiner Boeing; Ute Nöthlings; Antonia Trichopoulou; Eftihia Moutsiou; Vardis Dilis; Domenico Palli; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Paolo Vineis; Carla H van Gils; Petra H M Peeters; Eiliv Lund; Inger T Gram; Laudina Rodríguez; Antonio Agudo; Nerea Larrañaga; María-José Sánchez; Carmen Navarro; Aurelio Barricarte; Jonas Manjer; Björn Lindkvist; Malin Sund; Weimin Ye; Sheila Bingham; Kay-Tee Khaw; Andrew Roddam; Tim Key; Paolo Boffetta; Eric J Duell; Mazda Jenab; Valentina Gallo; Elio Riboli Journal: Int J Cancer Date: 2010-05-15 Impact factor: 7.396
Authors: D T Silverman; M Schiffman; J Everhart; A Goldstein; K D Lillemoe; G M Swanson; A G Schwartz; L M Brown; R S Greenberg; J B Schoenberg; L M Pottern; R N Hoover; J F Fraumeni Journal: Br J Cancer Date: 1999-08 Impact factor: 7.640
Authors: Jung Hyun Jo; In Rae Cho; Jang Han Jung; Hee Seung Lee; Moon Jae Chung; Seungmin Bang; Seung Woo Park; Jae Bock Chung; Si Young Song; Jeong Youp Park Journal: PLoS One Date: 2017-06-26 Impact factor: 3.240
Authors: Sara Lindström; Hilary Finucane; Brendan Bulik-Sullivan; Fredrick R Schumacher; Christopher I Amos; Rayjean J Hung; Kristin Rand; Stephen B Gruber; David Conti; Jennifer B Permuth; Hui-Yi Lin; Ellen L Goode; Thomas A Sellers; Laufey T Amundadottir; Rachael Stolzenberg-Solomon; Alison Klein; Gloria Petersen; Harvey Risch; Brian Wolpin; Li Hsu; Jeroen R Huyghe; Jenny Chang-Claude; Andrew Chan; Sonja Berndt; Rosalind Eeles; Douglas Easton; Christopher A Haiman; David J Hunter; Benjamin Neale; Alkes L Price; Peter Kraft Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-21 Impact factor: 4.254